publication, as of 2026-01-08Stale
https://pubmed.ncbi.nlm.nih.gov/41508550/
VENTURE was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of weekly subcutaneous VK2735, a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist. Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction.
Obesity (Silver Spring) 2026;34:537-549, PMID 41508550, abstract
registry, as of 2026-04-07Stale
https://clinicaltrials.gov/study/NCT07104383
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 1100. Conditions Weight Loss. This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obe
ClinicalTrials.gov NCT07104383 protocol and results modules
Registry NCT06068946
Phase Phase 2
Status Completed
Enrollment 176
Start 2023-08-31
Primary completion 2024-02-27
Study completion 2024-04-02
VK2735 2.5 mg
Dose 2.5 mg
Regimen once weekly
Weeks 13
Comparator placebo
Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.
percent change from baseline in body weight, -9.1 %, week 13
change in body weight, -9.2 kg, week 13
VK2735 15 mg
Dose 15 mg
Regimen once weekly
Weeks 13
Comparator placebo
Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.
percent change from baseline in body weight, -14.7 %, week 13
change in body weight, -14.6 kg, week 13
Placebo 13 weeks
Regimen once weekly
Weeks 13
Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.
percent change from baseline in body weight, -1.7 %, week 13
change in body weight, -1.8 kg, week 13
Registry NCT07104500
Phase Phase 3
Status Active, not recruiting
Enrollment 4500
Start 2025-06-23
Primary completion 2027-07-01
Catalyst Primary completion. 2027-07-01Stale
Active Assignment (Dose 1)
Active Assignment (Dose 2)
Active Assignment (Dose 3)
Registry NCT07104383
Phase Phase 3
Status Active, not recruiting
Enrollment 1100
Start 2025-06-23
Primary completion 2027-07-01
Study completion 2027-08-01
Catalyst Primary completion. 2027-07-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
Placebo Assignment
Regimen once weekly
Population Weight Loss
Active Assignment (Dose #1)
Regimen once weekly
Comparator placebo
Population Weight Loss
Active Assignment (Dose #2)
Regimen once weekly
Comparator placebo
Population Weight Loss
Active Assignment (Dose #3)
Regimen once weekly
Comparator placebo
Population Weight Loss